Marketing Orthocell to Professional Sport, page-15

Pleasure all. I just got filled on the bid at $0.48 for another 10,000 personally. Its difficult watching this stock meander whilst the ASX200 rallies, but do you want to buy CSL at what 50 times P/E? Or rather a company with proven products, dwindling in terms of share price due to its anonymity, that is very likely to sign a major partnership with its long term collaborative partner this quarter - the biggest medical company in the world by revenue?

As an ATI recipient I have been on this stock since its IPO because of ATI. CelGro was an unanticipated and enthralling bonus. But it has still been a poor return and long taxing wait for this partnership, that I think you will find has only been delayed by difficulties procuring patients that fit the requirements - they are very specific after all.

I can't predict the future anymore than the rest of you, but I can say watch this space in the next couple of months with some confidence. If a J&J partnership emerges and some ATI treatment of domestic sports-stars catches media attention, OCC will likely take off. Or more to the point, trade at prices that more decently reflect its future earnings potential. MSB has taken off after a recent update. PAR is trading higher on upcoming trial announcements. OCC is a frustrating laggard, but the potential catalyst is finally getting close.